Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2021 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
March 08, 2021 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
February 24, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress

Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 ...
February 22, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
February 19, 2021 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
January 08, 2021 16:26 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
January 06, 2021 00:30 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
January 04, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
December 06, 2020 10:05 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response...
December 04, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release...